Elsilimomab (Orphan Pharma international)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameElsilimomab (Orphan Pharma international)
Drug Alias NameBE-8Anti-interleukin 6 monoclonal antibody
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionInterleukin-6 inhibitors
TargetsInterleukin-6
Therapy Area/IndicationsMultiple MyelomaLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma

Other Information

ATC CodeN/A
Related LinksN/A